9-ING-41 in Patients With Advanced Cancers

Study Purpose

GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Patient - 1.
Is able to understand and voluntarily sign a written informed consent and is willing and able to comply with the protocol requirements including scheduled visits, treatment plan, laboratory tests and other study procedures. 2. Is aged ≥ 18 years. 3. Has pathologically confirmed advanced or metastatic malignancy characterized by one or more of the following: 1. Patient is intolerant of existing therapy(ies) known to provide clinical benefit for their condition. 2. Malignancy is refractory to existing therapy(ies) known to potentially provide clinical benefit. 3. Malignancy has relapsed after standard therapy. 4. Malignancy for which there is no standard therapy that improves survival by at least 3 months. 4. Has evaluable tumor(s) by standard radiological and/or laboratory assessments as applicable to their malignancy
  • - in Part 3, patients with solid tumors must have least 1 measurable lesion per response evaluation criteria in solid tumors (RECIST) v1.1 criteria, measured preferably by computed tomography (CT) scan or magnetic resonance image (MRI).
In the case of patients with glioblastoma multiforme (GBM) or other central nervous system (CNS) tumors, the tumor must be measurable, defined as a clearly enhancing tumor with at two perpendicular diameters at entry equal or superior to 1cm. 5. Has laboratory function within specified parameters (may be repeated): 1. Adequate bone marrow function: absolute neutrophil count (ANC) ≥ 500/mL; hemoglobin ≥ 8.5 g/dL, platelets ≥ 50,000/mL. 2. Adequate liver function: transaminases (aspartate aminotransferase/ alanine aminotransferase, AST/ALT) and alkaline phosphatase ≤ 3 (≤ 5 X the upper limit of normal (ULN) in the setting of liver metastasis or infiltration with malignant cells) x ULN; bilirubin ≤ 1.5 x ULN. 3. Adequate renal function: creatinine clearance ≥ 60 mL/min (Cockcroft and Gault) 4. Adequate blood coagulation: international normalized ratio (INR) ≤ 2.3. 5. Serum amylase and lipase ≤ 1.5 x ULN. 6. Has adequate performance status (PS): Eastern Co-operative Oncology Group (ECOG) PS 0-2. 7. Has received the final dose of any of the following treatments/ procedures with the specified minimum intervals before first dose of study drug (unless in the opinion of the investigator and the study medical coordinator the treatments/ procedures will not compromise patient safety or interfere with study conduct and with IDMC agreement):
  • - Chemotherapy, immunotherapy, or systemic radiation therapy - 14 days or ≥ 5 half-lives (whichever is shorter) - Focal radiation therapy - 7 days.
  • - Systemic and topical corticosteroids - 7 days.
  • - Surgery with general anesthesia - 7 days.
  • - Surgery with local anesthesia - 3 days.
8. May continue endocrine therapies (e.g. for breast or prostate cancer) and/or anti-human epidermal growth factor (Her2) therapies while on this study. 9. Women of childbearing potential must have a negative baseline blood or urine pregnancy test within 72 hours of first study therapy. Women may be neither breastfeeding nor intending to become pregnant during study participation and must agree to use effective contraceptive methods (hormonal or barrier method of birth control, or true abstinence) for the duration of study participation and in the following 90 days after discontinuation of study treatment. 10. Male patients with partners of childbearing potential must take appropriate precautions to avoid fathering a child from screening until 90 days after discontinuation of study treatment and use appropriate barrier contraception or true abstinence. 11. Must not be receiving any other investigational medicinal product.

Exclusion Criteria:

  • - Patient - 1.
Is pregnant or lactating. 2. Is known to be hypersensitive to any of the components of 9-ING-41 or to the excipients used in its formulation. 3. Has not recovered from clinically significant toxicities as a result of prior anticancer therapy, except alopecia and infertility. Recovery is defined as ≤ Grade 2 CTCAE Version 4.03. 4. Has significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, or stroke within 6 months of the first dose of 9-ING-41, or cardiac arrhythmia requiring medical treatment detected at screening. 5. Has had a myocardial infarction within 12 weeks of the first dose of 9-ING-41 or has electrocardiogram (ECG) abnormalities that are deemed medically relevant by the investigator or study medical coordinator. 6. Has known symptomatic rapidly progressive brain metastases or leptomeningeal involvement as assessed by CT scan or MRI. Patients with stable asymptomatic brain metastases or leptomeningeal disease or slowly progressive disease are eligible provided that they have not required new treatments for this disease in a 28-day period before the first dose of study drug, and anticonvulsants and steroids are at a stable dose for a period of 14 days prior to the first dose of study drug. 7. Has had major surgery (not including placement of central lines) within 7 days prior to study entry or is planned to have major surgery during the course of the study (major surgery may be defined as any invasive operative procedure in which an extensive resection is performed, e.g. a body cavity is entered, organs are removed, or normal anatomy is altered. In general, if a mesenchymal barrier is opened (pleural cavity, peritoneum, meninges), the surgery is considered major) 8. Has any medical and/or social condition which, in the opinion of the investigator or study medical coordinator would preclude study participation. 9. Has received an investigational anti-cancer drug in the 14-day period before the first dose of study drug (or within 5 half-lives if longer) or is currently participating in another interventional clinical trial. 10. Has a current active malignancy other than the target cancer. 11. Is considered to be a member of a vulnerable population (for example, prisoners) Part 3 ARMB

Inclusion Criteria:

Patient
  • - 1.
Is able to understand and voluntarily sign a written informed consent and is willing and able to comply with the protocol requirements including scheduled visits, treatment plan, laboratory tests and other study procedures. 2. Is aged ≥ 18 years. 3. Has pathologically confirmed metastatic pancreatic cancer AND is previously untreated with systemic agents in the recurrence/metastatic setting. 4. Must have at least 1 measurable lesion per RECIST v1.1, measured preferably by computed tomography (CT) scan or magnetic resonance image (MRI) 5. Has laboratory function within specified parameters (may be repeated): e. Adequate bone marrow function: absolute neutrophil count (ANC) ≥ 500/mL; hemoglobin ≥ 8.5 g/dL, platelets ≥ 75,000/mL f. Adequate liver function: transaminases (aspartate aminotransferase/ alanine aminotransferase, AST/ALT) and alkaline phosphatase ≤ 3 (≤ 10 X the upper limit of normal (ULN) in the setting of liver metastasis or infiltration with malignant cells) x ULN; bilirubin ≤ 1.5 x ULN Adequate renal function: creatinine clearance ≥ 30 mL/min (Cockcroft and Gault) 6. Has Eastern Co-operative Oncology Group (ECOG) PS 0 or 1. 7. Has received the final dose of any of the following treatments/ procedures with the specified minimum intervals before first dose of study drug:
  • - Focal radiation therapy - 7 days.
  • - Surgery with general anesthesia - 7 days.
  • - Surgery with local anesthesia - 3 days.
8. May have received treatment with fluorouracil or gemcitabine as a radiation sensitizer in the adjuvant setting if the treatment was received at least 6 months before study enrollment. 9. May have received neoadjuvant chemotherapy with FOLFIRINOX if last dose given at least 6 months before study enrollment. 10. May have received prior cytotoxic doses of systemic chemotherapy in the adjuvant setting if last dose given at least 6 months before study enrollment. 11. Women of childbearing potential must have a negative baseline blood or urine pregnancy test within 72 hours of first study therapy. Women may be neither breastfeeding nor intending to become pregnant during study participation and must agree to use effective contraceptive methods (hormonal or barrier method of birth control, or true abstinence) for the duration of study participation and in the following 90 days after discontinuation of study treatment. 12. Male patients with partners of childbearing potential must take appropriate precautions to avoid fathering a child from screening until 90 days after discontinuation of study treatment and use appropriate barrier contraception or true abstinence. 13. Must not be receiving any other investigational medicinal product. Patient who meets ANY of the following criteria is not eligible for this Part 3 study Arm B:

Exclusion Criteria:

1. Is pregnant or lactating. 2. Is known to be hypersensitive to any of the components of 9-ING-41 or to the excipients used in its formulation. 3. Has endocrine or acinar pancreatic carcinoma. 4. Has not recovered from clinically significant toxicities as a result of prior anticancer therapy, except alopecia and/or infertility. Recovery is defined as ≤ Grade 2 severity per CTCAE, v5.0. 5. Has significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina, or stroke within 6 months of the first dose of study therapy, or uncontrolled cardiac arrhythmia. 6. Has had a myocardial infarction within 12 weeks of the first dose of study therapy or has electrocardiogram (ECG) abnormalities that are deemed medically relevant by the investigator. 7. Has symptomatic rapidly progressive brain metastases or leptomeningeal involvement as assessed by CT scan or MRI. Patients with stable brain metastases or leptomeningeal disease or slowly progressive disease are eligible provided that they have not required new treatments for this disease in a 28-day period before the first dose of study drug, and anticonvulsants and steroids are at a stable dose for a period of 14 days prior to the first dose of study drug. 8. Has had major surgery (not including placement of central lines) within 7 days prior to study entry or is planned to have major surgery during the course of the study (major surgery may be defined as any invasive operative procedure in which an extensive resection is performed, e.g., a body cavity is entered, organs are removed, or normal anatomy is altered. In general, if a mesenchymal barrier is opened (pleural cavity, peritoneum, meninges), the surgery is considered major) 9. Has any medical and/or social condition which, in the opinion of the investigator or study medical coordinator would preclude study participation. 10. Has received an investigational anti-cancer drug in the 14-day period before the first dose of study drug (or within 5 half-lives if longer) or is currently participating in another interventional clinical trial. 11. Has a current active malignancy other than pancreatic cancer. 12. Is considered to be a member of a vulnerable population (for example, prisoners).

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT03678883
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Actuate Therapeutics Inc.
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

N/A
Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Active, not recruiting
Countries Belgium, Canada, France, Netherlands, Portugal, Spain, United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
Additional Details

9-ING-41 is a first-in-class, intravenously administered, maleimide-based small molecule potent selective GSK-3β inhibitor with significant pre-clinical antitumor activity. GSK-3 is a serine/threonine kinase initially described as a key regulator of metabolism and has a role in diverse disease processes including cancer, immune disorders, pathologic fibrosis, metabolic disorders, and neurological disorders. GSK-3 has two ubiquitously expressed and highly conserved isoforms, GSK-3α and GSK-3β, with both shared and distinct substrates and functional effects. GSK-3β is particularly important in tumor progression and modulation of oncogenes (including beta-catenin, cyclin D1 and c-Myc), cell cycle regulators (e.g. p27Kip1) and mediators of epithelial-mesenchymal transition (e.g. zinc finger protein SNAI1, Snail). Aberrant overexpression of GSK-3β has been shown to promote tumor growth and chemotherapy resistance in various solid tumors including colon, ovarian, and pancreatic cancers and glioblastoma through differential effects on the pro-survival nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and c-Myc pathways as well on tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and p53-mediated apoptotic mechanisms. GSK-3β helps maintain malignant cell survival and proliferation, particularly in terms of mediating resistance to standard anti-cancer therapies, through the NF-κB pathway. GSK-3β has been established as a potential anticancer target in human bladder, breast, colorectal, glioblastoma, lung, neuroblastoma, ovarian, pancreatic, prostate, renal and thyroid cancers as well as chronic lymphocytic leukemia and lymphomas. 9-ING-41 is a small molecule potent selective GSK-3β inhibitor with broad spectrum pre-clinical antitumor activity. It's modes of action include downregulation of NF-κB and decreasing the expression NF-κB target genes including cyclin D1, Bcl-2, anti-apoptotic protein (XIAP) and B-cell lymphoma-extra large (Bcl-XL) leading to inhibition of tumor growth in multiple solid tumor cell and lymphoma lines and patient derived xenograft (PDX) models. NF-κB is constitutively active in cancer cells and promotes anti-apoptotic molecule expression. NF-κB activation is particularly important in cancer cells that have become chemo- and/or radio-resistant. 9-ING-41 also has significant activity in pre-clinical models of pathological pleural and pulmonary fibrosis. 9-ING-41 has significant in vitro and in vivo activity as a single agent and/or in combination with standard cytotoxic chemotherapies in a spectrum of solid tumors and hematological malignancies including bladder, breast, glioblastoma, neuroblastoma, pancreatic, sarcomas, and renal cancers as well as lymphomas. The 1801 had three parts:

  • - Completed: Part 1 (9-ING-41 as monotherapy): The standard 3+3 dose escalation design will be applied to all dose cohorts until the Maximum Tolerated Dose (MTD) or Recommended Phase 2 Dose (RP2D) is identified.
  • - Completed: 9-ING-41 combined with standard anticancer agents: The 3+3 dose escalation study design will be used for 8 chemotherapy combination regimens (9-ING-41 plus gemcitabine, doxorubicin, lomustine, carboplatin, irinotecan, nab-paclitaxel plus gemcitabine, paclitaxel plus carboplatin, pemetrexed plus carboplatin) to identify the MTD/RP2D of each regimen.
  • - Part 3: A randomized Phase 2 study of 9-ING-41 either once or twice weekly with gemcitabine and nab-paclitaxel (GA) versus GA alone for patients with previously untreated metastatic or locally advanced pancreatic cancer is now open.

Arms & Interventions

Arms

Experimental: 9-ING-41

Drug: 9-ING-41

Experimental: 9-ING-41 plus Gemcitabine

Drugs: Gemcitabine - 21 day cycle. 9-ING-41

Experimental: 9-ING-41 plus Doxorubicin

Drugs: Doxorubicin. 9-ING-41

Experimental: 9-ING-41 plus Lomustine

Drugs: Lomustine. 9-ING-41.

Experimental: 9-ING-41 plus Carboplatin

Drugs: Carboplatin. 9-ING-41.

Experimental: 9-ING-41 plus nab paclitaxel Gemcitabine

Drugs: Nab-paclitaxel. Gemcitabine - 28 day cycle. 9-ING-41.

Experimental: 9-ING-41 plus Paclitaxel/Carboplatin

Drugs: Paclitaxel. Carboplatin. 9-ING-41.

Experimental: 9-ING-41 plus Irinotecan

Drugs: Irinotecan. 9-ING-41.

Interventions

Drug: - 9-ING-41

Starting dose of-9-ING-41 will be administered on Day 1 and 4 each week of a 21-day cycle. 9-ING-41 will be administered intravenously over 60 minutes.

Drug: - Gemcitabine - 21 day cycle

Gemcitabine 1250 mg/m2 as a 30-minute intravenous infusion on Days 1 and 8 of a 21-day cycle

Drug: - Doxorubicin.

Doxorubicin 75 mg/m2, intravenous bolus on Day 1 of a 21-day cycle up to a maximum lifetime dose of 550 mg/m2.

Drug: - Lomustine

Lomustine 30 mg/m² orally as a single dose, weekly for twelve weeks.

Drug: - Carboplatin.

Carboplatin AUC 6 IV over 1 hour on Day 1 of a 21-day cycle.

Drug: - Nab paclitaxel.

Nab-paclitaxel 125 mg/m2 intravenously on Days 1, 8 and 15 of a 28-day cycle

Drug: - Paclitaxel.

Paclitaxel 175 mg/m2 intravenously over 3 hours on Day 1 of a 21-day cycle.

Drug: - Gemcitabine - 28 day cycle

Gemcitabine 1000 mg/m2 intravenously over 30-minutes on Days 1, 8 and 15 of a 28-day cycle

Drug: - Irinotecan

Irinotecan 350 mg/m2 intravenously over 90-minutes on Day 1 of a 21-day cycle

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Mayo Clinic, Phoenix, Arizona

Status

Address

Mayo Clinic

Phoenix, Arizona, 85054

Arizona Oncology Associates, Tucson, Arizona

Status

Address

Arizona Oncology Associates

Tucson, Arizona, 85704

The University of Arizona Cancer Center, Tucson, Arizona

Status

Address

The University of Arizona Cancer Center

Tucson, Arizona, 85719

University of California Irvine Health, Orange, California

Status

Address

University of California Irvine Health

Orange, California, 92868

San Francisco, California

Status

Address

UCSF Helen Diller Family Comprehensive Cancer Center

San Francisco, California, 94115

Christiana Care Health Services, Newark, Delaware

Status

Address

Christiana Care Health Services

Newark, Delaware, 19709

Sibley Memorial Hospital, Washington, District of Columbia

Status

Address

Sibley Memorial Hospital

Washington, District of Columbia, 20016

Florida Cancer Specialists - South, Fort Myers, Florida

Status

Address

Florida Cancer Specialists - South

Fort Myers, Florida, 33901

Miami Cancer Institute, Miami, Florida

Status

Address

Miami Cancer Institute

Miami, Florida, 33176

Florida Cancer Specialists - North, Saint Petersburg, Florida

Status

Address

Florida Cancer Specialists - North

Saint Petersburg, Florida, 33705

Chicago, Illinois

Status

Address

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Chicago, Illinois, 60611

Des Moines Oncology Research Association, Des Moines, Iowa

Status

Address

Des Moines Oncology Research Association

Des Moines, Iowa, 50309

Kansas University Cancer Center, Kansas City, Kansas

Status

Address

Kansas University Cancer Center

Kansas City, Kansas, 66160

Ochsner Clinic Foundation, New Orleans, Louisiana

Status

Address

Ochsner Clinic Foundation

New Orleans, Louisiana, 70121

University of Michigan, Ann Arbor, Michigan

Status

Address

University of Michigan

Ann Arbor, Michigan, 48109

Minneapolis, Minnesota

Status

Address

MetroMetro-Minnesota Community Oncology Research Consortium (MMCORC)

Minneapolis, Minnesota, 55416

Mayo Clinic, Rochester, Minnesota

Status

Address

Mayo Clinic

Rochester, Minnesota, 55905

Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada

Status

Address

Comprehensive Cancer Centers of Nevada

Las Vegas, Nevada, 89128

Morristown Medical Center, Morristown, New Jersey

Status

Address

Morristown Medical Center

Morristown, New Jersey, 07960

Capital Health Medical Center/ Hopewell, Pennington, New Jersey

Status

Address

Capital Health Medical Center/ Hopewell

Pennington, New Jersey, 08534

MD Anderson Cancer Center at Cooper, Voorhees, New Jersey

Status

Address

MD Anderson Cancer Center at Cooper

Voorhees, New Jersey, 08043

New York, New York

Status

Address

Columbia University- Irving Medical Center

New York, New York, 10032

Stony Brook University Hospital, Stony Brook, New York

Status

Address

Stony Brook University Hospital

Stony Brook, New York, 11794

Duke University Medical Center, Durham, North Carolina

Status

Address

Duke University Medical Center

Durham, North Carolina, 27710

Oregon Health and Science University, Portland, Oregon

Status

Address

Oregon Health and Science University

Portland, Oregon, 97239

St. Luke's University Health Network, Bethlehem, Pennsylvania

Status

Address

St. Luke's University Health Network

Bethlehem, Pennsylvania, 18015

Allegheny Health Network, Pittsburgh, Pennsylvania

Status

Address

Allegheny Health Network

Pittsburgh, Pennsylvania, 15212

Rhode Island Hospital, Providence, Rhode Island

Status

Address

Rhode Island Hospital

Providence, Rhode Island, 02903

Prisma Health Cancer Institute, Greenville, South Carolina

Status

Address

Prisma Health Cancer Institute

Greenville, South Carolina, 26905

Sanford Research, Sioux Falls, South Dakota

Status

Address

Sanford Research

Sioux Falls, South Dakota, 57105

West Cancer Center, Germantown, Tennessee

Status

Address

West Cancer Center

Germantown, Tennessee, 38138

Baptist Clinical Research Institute, Memphis, Tennessee

Status

Address

Baptist Clinical Research Institute

Memphis, Tennessee, 38120

Nashville, Tennessee

Status

Address

Sarah Cannon Research Institute- Tennessee Oncology-Nashville

Nashville, Tennessee, 37203

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee

Status

Address

Vanderbilt-Ingram Cancer Center

Nashville, Tennessee, 37232

Dallas, Texas

Status

Address

Texas Oncology- Charles A. Sammons Cancer Center

Dallas, Texas, 75246

UT Southwestern Medical Center, Dallas, Texas

Status

Address

UT Southwestern Medical Center

Dallas, Texas, 75390

Utah Cancer Specialists, Salt Lake City, Utah

Status

Address

Utah Cancer Specialists

Salt Lake City, Utah, 84124

Fred Hutchinson Cancer Research Center, Seattle, Washington

Status

Address

Fred Hutchinson Cancer Research Center

Seattle, Washington, 98109

West Virginia University, Morgantown, West Virginia

Status

Address

West Virginia University

Morgantown, West Virginia, 26506

UW Carbone Cancer Center, Madison, Wisconsin

Status

Address

UW Carbone Cancer Center

Madison, Wisconsin, 53792

International Sites

UZA- Antwerpen, Edegem, Antwerp, Belgium

Status

Address

UZA- Antwerpen

Edegem, Antwerp, 2650

Imelda VZW, Bonheiden, Belgium

Status

Address

Imelda VZW

Bonheiden, , 2820

UZ Gent, Gent, Belgium

Status

Address

UZ Gent

Gent, , 9000

UZ Leuven Gasthuisberg, Leuven, Belgium

Status

Address

UZ Leuven Gasthuisberg

Leuven, , 3000

Cross Cancer Institute, Edmonton, Alberta, Canada

Status

Address

Cross Cancer Institute

Edmonton, Alberta, T6G 1Z2

QE II Health Sciences Centre, Halifax, Nova Scotia, Canada

Status

Address

QE II Health Sciences Centre

Halifax, Nova Scotia, B3H 2Y9

Greenfield Park, Quebec, Canada

Status

Address

Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre

Greenfield Park, Quebec, G4V 2H1

Jewish General Hospital, Montréal, Quebec, Canada

Status

Address

Jewish General Hospital

Montréal, Quebec, H3T 1E2

McGill University Health Centre, Montréal, Quebec, Canada

Status

Address

McGill University Health Centre

Montréal, Quebec, H4A 3J1

Sherbrooke, Quebec, Canada

Status

Address

Centre Hospitalier Universitaire de Sherbrooke

Sherbrooke, Quebec, J1H 5N4

Besançon, Bourgogne-Franche-Comte, France

Status

Address

Center Hospitalier Regional Universitaire de Besancon - Site Jean Minjoz

Besançon, Bourgogne-Franche-Comte, 25030

CHRU Brest Hopital Morvan, Brest, Bretagne, France

Status

Address

CHRU Brest Hopital Morvan

Brest, Bretagne, 29200

Hopital Claude Huriez, Lille, Hauts De France, France

Status

Address

Hopital Claude Huriez

Lille, Hauts De France, 59037

Institute de Cancerologie de Lorraine, Vandœuvre-lès-Nancy, Meurthe-et-Moselle, France

Status

Address

Institute de Cancerologie de Lorraine

Vandœuvre-lès-Nancy, Meurthe-et-Moselle, 54500

Institut Bergonie, Bordeaux, Nouvelle Aquitaine, France

Status

Address

Institut Bergonie

Bordeaux, Nouvelle Aquitaine, 33076

Insitut de Cancerologie de l'Ouest, Saint-Herblain, Pays-de-la-Loire, France

Status

Address

Insitut de Cancerologie de l'Ouest

Saint-Herblain, Pays-de-la-Loire, 44800

Hopital de la Timone, Marseille, France

Status

Address

Hopital de la Timone

Marseille, , 13005

Netherlands Cancer Institute, Amsterdam, Netherlands

Status

Address

Netherlands Cancer Institute

Amsterdam, , 1066 CX

Fundacao Champalimaud, Lisbon, Portugal

Status

Address

Fundacao Champalimaud

Lisbon, , 1400-038

Hospital Da Luz, Lisbon, Portugal

Status

Address

Hospital Da Luz

Lisbon, , 1500-650

Centro Hospitalar Universitario Sao Joao, Porto, Portugal

Status

Address

Centro Hospitalar Universitario Sao Joao

Porto, , 4200-319

Vall d'Hebron Institute of Oncology, Barcelona, Spain

Status

Address

Vall d'Hebron Institute of Oncology

Barcelona, , 08035

Institut Catala d'Oncologia, Barcelona, Spain

Status

Address

Institut Catala d'Oncologia

Barcelona, , 8908

Hospital Clinico U San Carlos (HSC), Madrid, Spain

Status

Address

Hospital Clinico U San Carlos (HSC)

Madrid, , 28050

Madrid, Spain

Status

Address

START Madrid-HM CIOCC Hospital Universitario

Madrid, , 28050

INCLIVA University of Valencia, Valencia, Spain

Status

Address

INCLIVA University of Valencia

Valencia, , 46010

Stay Informed & Connected